Impact Factor: 3.294Five-Year Impact Factor: 3.380? 2017 Thomson Reuters, Journal Citation Reports ? for 2016 ranks Cancer Biology & Therapy 92 out of 217 in Oncology.Aims & Scope: Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.

影響因子:3.294五年影響因子:3.380Thomson Reuters, Journal Citation Reports?for 2016將癌癥生物學(xué)和治療在217個(gè)腫瘤學(xué)領(lǐng)域中排名92位。目標(biāo)和范圍:癌癥是第二大致死原因，是一個(gè)由100多種疾病組成的異質(zhì)性群體。癌癥的特征是細(xì)胞和基質(zhì)細(xì)胞的無(wú)序和不受控制的增殖，伴隨著細(xì)胞死亡的減少，在營(yíng)養(yǎng)和生長(zhǎng)因子缺乏、缺氧和細(xì)胞間接觸減少的壓力下，細(xì)胞能夠存活。在分子水平上，癌癥是一種遺傳疾病，是由于體細(xì)胞隨時(shí)間積累突變而發(fā)展起來(lái)的。表型包括基因組不穩(wěn)定性和允許加速遺傳變化的染色體非整倍體。任何細(xì)胞的惡性轉(zhuǎn)化和腫瘤進(jìn)展都需要永生、檢查點(diǎn)失控、生長(zhǎng)失調(diào)和生存。關(guān)于伴隨腫瘤發(fā)展和進(jìn)展的大量細(xì)胞和分子遺傳變化以及宿主與腫瘤的相互作用已經(jīng)有了大量的了解。這是分子腫瘤學(xué)領(lǐng)域的目標(biāo)，利用這一知識(shí)來(lái)了解癌癥的發(fā)病機(jī)制和藥物作用，以及開發(fā)更有效的癌癥診斷和治療策略。這包括預(yù)防策略以及治療轉(zhuǎn)移的方法。隨著人類基因組序列和基因組和蛋白質(zhì)組方法的可用性，大量的工具和資源正在產(chǎn)生更多的信息。挑戰(zhàn)在于從這些信息中找出生物學(xué)意義，建立適當(dāng)?shù)哪Ｐ秃图僭O(shè)，并為臨床醫(yī)生和患者的利益翻譯信息?！栋┌Y生物學(xué)與治療》旨在發(fā)表關(guān)于癌癥分子基礎(chǔ)的原創(chuàng)研究，包括與診斷或治療相關(guān)的翻譯文章。我們將包括及時(shí)的評(píng)論涵蓋廣泛的期刊范圍。該雜志還將發(fā)表評(píng)論文章和感興趣的會(huì)議報(bào)告。其目標(biāo)是通過(guò)使用傳統(tǒng)和電子格式及時(shí)發(fā)表重要成果，促進(jìn)交流和迅速交換信息。該雜志和杰出的編輯委員會(huì)將努力保持在所有活動(dòng)的卓越的最高標(biāo)準(zhǔn)，以產(chǎn)生寶貴的資源。